Regression of left ventricular hypertrophy (LVH) in renal transplant recipients predicts a better long-term clinical outcome, researchers found.
In a prospective study, Ernesto Paoletti, MD, University of Genoa, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Genoa, Italy, and colleagues compared with 60 renal transplant recipients who experienced LVH regression and 40 recipients whose LVH remained unchanged or worsened. Subjects were participants in 2 randomized controlled trials aimed at evaluating the effect of active intervention on post-transplant LVH. The investigators evaluated the effect of LVH regression on a composite outcome of death and any cardiovascular (CV) or renal event.
During an 8.4-year follow-up, 8 deaths, 18 cardiovascular events, and 6 renal events occurred. In multivariable analysis, LVH regression was associated with a significant 58% decreased risk of the composite endpoint, Dr. Paoletti’s group reported online ahead of print in Nephrology Dialysis Transplantation.
Patients who experienced LVH regression had significantly better survival rates compared with those who did not, according to the researchers. Better graft function and LVH regression predicted a significantly decreased risk of the cardiovascular endpoint. In addition, patients who had a decrease in left ventricular mass index had a significantly improved cardiac event-free survival.